Stephanie Price is the Head of Content at PsychHealthNews. She specializes in health and wellness, with a focus on psychedelics and cannabis, covering topics such as health, science, and policy. Her work has been featured in notable publications including NR Times, AgeTech World, and Health Tech World.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Stephanie Price's coverage primarily focuses on the cannabis industry, including legalization, business, and research. She often covers government announcements and press releases related to the cannabis industry.
If you are working in the cannabis or psychedelics industries and have insights into regulatory changes, scientific developments, or impactful business initiatives within these fields, Stephanie could be a receptive audience for your expertise. Given her focus on governmental and private sector announcements in this space, offering exclusive data or expert commentary based on such events may increase your chances of engaging with her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Stephanie Price
Myant Corp has acquired digital health company mmHg in an acquisition that aims to accelerate personalised, AI-enabled remote healthcare.
A new collaboration between Mayo Clinic, Microsoft Research and Cerebras Systems in the field of generative AI is aiming to advance to personalize patient care, accelerate diagnostic time and improve accuracy.
AI is rapidly innovating the field of healthcare, however, ensuring diversity and inclusivity is key to accuracy and usefulness of data in order to truly transform quality of life and treatment outcomes.
By: Stephanie Price
A clinical trial investigating the treatment TIVDAK for cervical cancer has shown positive results.
By: Stephanie Price
A new collaboration is set to revolutionise pharmaceutical manufacturing with the use of advanced aseptic processing technology.
A urine-based diagnostic kit for bladder cancer that can be conveniently used at home and can accurately detect bladder cancer biomarkers without any pre-processing of urine samples has been developed by researchers.
FemTech medical device company Zero Candida Technologies has listed on the Frankfurt Stock Exchange (FSE) under the trading symbol “9L2”.
AI company Azra AI, has launched the newest release of its end-to-end oncology platform which enables personalised cancer treatment plans.
Europe's first private, women's health tissue bank has been launched by Liverpool-based laboratory and medical education provider BioGrad, backed by a £25m investment.
By: Stephanie Price
Telephone-delivered acceptance and commitment therapy (ACT) is beneficial for reducing fatigue's interference with functioning and improves the quality of life for survivors of metastatic breast cancer, a new study has revealed.
(833) 317-6278 
